Summary
Bristol-Myers Squibb Company (BMY) announced on November 5, 2020, its entry into a $4.0 billion Term Loan Credit Agreement, effective November 4, 2020. This new facility provides significant financial flexibility, with two tranches available on a delayed draw basis until April 9, 2021. The purpose of these funds is for general corporate uses, including potential debt repayment, indicating a proactive approach to managing its capital structure. The unsecured term loans are structured into a $2 billion 364-day tranche and a $2 billion two-year tranche, offering flexibility in maturity. Borrowings can bear interest at either a base rate or a Eurodollar rate, with margins dependent on the company's public debt ratings, suggesting a cost-efficient borrowing strategy tied to its creditworthiness. The agreement includes standard covenants and events of default typical for such facilities.
Key Highlights
- 1BMY entered into a $4.0 billion unsecured Term Loan Credit Agreement.
- 2The facility consists of two delayed-draw tranches: $2 billion over 364 days and $2 billion over two years, both available until April 9, 2021.
- 3Funds are designated for general corporate purposes, including debt repayment.
- 4Borrowings can be at either a base rate or Eurodollar rate, with margins linked to BMY's public debt ratings.
- 5The term loans are pre-payable without premium or penalty, subject to breakage costs.
- 6The agreement includes customary covenants and events of default.
- 7This action demonstrates proactive financial management and access to liquidity.